Innoviva (NASDAQ:INVA – Get Free Report) and Novartis (NYSE:NVS – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership.
Profitability
This table compares Innoviva and Novartis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Innoviva | 44.13% | 22.91% | 16.67% |
| Novartis | 18.11% | 41.04% | 14.45% |
Insider & Institutional Ownership
99.1% of Innoviva shares are held by institutional investors. Comparatively, 13.1% of Novartis shares are held by institutional investors. 2.0% of Innoviva shares are held by company insiders. Comparatively, 0.0% of Novartis shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Risk & Volatility
Innoviva has a beta of 0.38, suggesting that its share price is 62% less volatile than the S&P 500. Comparatively, Novartis has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent recommendations for Innoviva and Novartis, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Innoviva | 0 | 1 | 5 | 0 | 2.83 |
| Novartis | 3 | 9 | 6 | 0 | 2.17 |
Innoviva currently has a consensus price target of $39.00, suggesting a potential upside of 110.92%. Novartis has a consensus price target of $152.25, suggesting a potential downside of 4.86%. Given Innoviva’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Innoviva is more favorable than Novartis.
Valuation and Earnings
This table compares Innoviva and Novartis”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Innoviva | $438.32 million | 3.00 | $271.17 million | $1.99 | 9.29 |
| Novartis | $54.53 billion | 5.60 | $13.98 billion | $5.24 | 30.54 |
Novartis has higher revenue and earnings than Innoviva. Innoviva is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.
Summary
Novartis beats Innoviva on 8 of the 14 factors compared between the two stocks.
About Innoviva
Innoviva, Inc. is a biopharmaceutical company with two main areas of activity: royalty interests in respiratory medicines developed with GSK and the development and commercialization of specialty medicines. Its respiratory-related royalties include products such as Trelegy Ellipta, Anoro Ellipta and Breo Ellipta, which are used to treat chronic obstructive pulmonary disease and asthma and are marketed by GSK. Through its specialty therapeutics operations, Innoviva focuses on medicines for serious infections and other acute-care conditions.
About Novartis
Novartis AG is a Swiss pharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative medicines. Its research and products address conditions in areas including oncology, immunology, neuroscience, and cardiovascular, renal and metabolic health. The company’s medicines include treatments such as Kisqali for certain breast cancers, Cosentyx for inflammatory diseases, Entresto for heart failure and Kesimpta for multiple sclerosis. Its portfolio also includes radioligand therapies and other specialized treatments.
Receive News & Ratings for Innoviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva and related companies with MarketBeat.com's FREE daily email newsletter.
